http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2708215-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 |
| filingDate | 2015-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd6a2753b427d9a35a424f9a1fdec845 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21aeab9d30ea778851334463af44164c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_871e39bba9845aa6f0ded541239acb87 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4da64d088248f04e1bebcddfa8a37822 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cac3221f46a474ad0841ccd2703617f |
| publicationDate | 2019-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2708215-T3 |
| titleOfInvention | Compounds of 6,7-dihydropyrazolo [1,5-a] pyrazin-4 (5H) -one and their use as negative allosteric modulators of MGLU2 receptors |
| abstract | A compound of Formula (I) ** Formula ** or a stereoisomeric form thereof, wherein R 1 is phenyl or 2-pyridinyl, each optionally substituted by one or more substituents each independently selected from the group consisting of halo, alkyl C 1-4, monohalo-C 1-4 alkyl, polyhalo-C 1-4 alkyl, C 1-4 alkyl- OH, -CN, -C 1-4 alkyl-O-C 1-4 alkyl, C 3-7 cycloalkyl, -O- C 1-4 alkyl, monohaloC 1-4 alkyl, polyhaloC 1-4 alkyl, SF 5, C 1-4 alkyl, monohaloC 1-4 alkyl, and polyhaloC 1-4 alkyl; R2 is selected from the group consisting of hydrogen; C1-4 alkyl; C3-7 cycloalkyl; Het1; Arilo; -C (O) R5; -C (O) Het2; Het2; and C 1-4 alkyl substituted by one or more substituents each independently selected from the group consisting of halo, C 3-7 cycloalkyl, Aryl, Het 1 and Het 2; wherein R 5 is selected from the group consisting of hydrogen, C 1-4 alkyl and C 3-7 cycloalkyl; Aryl is phenyl optionally substituted by one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyl, C 1-4 alkyl-OH, monohalo-C 1-4 alkyl, polyhalo-C 1-4 alkyl, -CN , -O-C1-4alkyl, -OH, -C1-4alkyl-O-C1-4alkyl, -NR'R ", -NHC (O) C1-4alkyl, -C (O) NR'R" , -C (O) NH [C (O) C1-4alkyl], -S (O) 2NR'R ", - S (O) 2NH [C (O) C1-4alkyl] and -SO2-C1alkyl -4; Het1 is selected from the group consisting of oxetanyl, tetrahydrofuranyl and tetrahydropyranyl; Het2 is (a) a 6-membered aromatic heterocyclyl substituent selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl, each of which it may be optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyl, C 1-4 alkyl-OH, C 1-4 monohaloalkyl, polyhaloC 1-4 alkyl, -CN, -O- C 1-4 alkyl, -OH, -C 1-4 alkyl-O-C 1-4 alkyl, -NR'R ", -NHC (O) C 1-4 alkyl, -C (O) NR'R", -C (O) NH [C (O) C 1-4 alkyl], -S (O) 2 NR'R ", -S (O) 2 NH [C (O) C 1-4 alkyl] and -SO 2 -C 1-4 alkyl; or (b) a 5-membered aromatic heterocyclyl selected from the group consisting of thiazolyl, oxazolyl, 1H pyrazolyl and 1H-imidazolyl, each of which may be optionally substituted with one or more substituents each independently selected from the group consisting in halo, C 1-4 alkyl, -C 1-4 alkyl-OH, C 1-4 monohaloalkyl, polyhalo-C 1-4 alkyl, -CN, -O-C 1-4 alkyl, -OH, -C 1-4 alkyl-O- C 1-4 alkyl, -NR'R ", -NHC (O) C 1-4 alkyl, -C (O) NR'R", -C (O) NH [C (O) C 1-4 alkyl], -S (O) 2NR'R ", -S (O) 2NH [C (O) C 1-4 alkyl] and -SO 2 -C 1-4 alkyl, each R 'and R" is independently selected from hydrogen and C 1-4 alkyl; R3 is selected from hydrogen and C1-4alkyl; and R 4 is selected from the group consisting of hydrogen, C 1-4 alkyl, monohalo-C 1-4 alkyl, polyhalo-C 1-4 alkyl, C 1-4 alkyl-O-C 1-4 alkyl and C 1-4 alkyl-OH ; or an N-oxide, or a pharmaceutically acceptable salt or a solvate thereof. |
| priorityDate | 2014-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 618.